Nanoparticle Characterization for Cancer Therapeutics and Diagnostics: Lessons Learned from NCI’s Nanotechnology Characterization Lab (NCL)
- At: 2012 FIP Congress in Amsterdam (the Netherlands)
- Type: Presentation
- By: MCNEIL, Scott (Frederick National Lab for Cancer Research, SAIC-Frederick/Nanotechnology Characterization Lab, Frederick, United States of America)
AbstractNCI's Nanotechnology Characterization Laboratory (NCL) conducts preclinical efficacy and toxicity testing of nanoparticles intended for cancer therapeutics and diagnostics. The NCL is a collaborating partnership between NCI, the U.S. Food and Drug Administration (FDA) and the National Institute of Standards and Technology (NIST). The NCL.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.